Sort   by:  
 Page size 
UnknownIdentification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
Not available
S-EPMC3709460 | biostudies-literature
UnknownDevelopment of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.
Not available
S-EPMC10214179 | biostudies-literature
UnknownClinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
Not available
S-EPMC7666431 | biostudies-literature
UnknownOlfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort.
Not available
S-EPMC12464792 | biostudies-literature
UnknownSex Differences in Long COVID.
Not available
S-EPMC11755195 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownMeasurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study.
Not available
S-EPMC11578795 | biostudies-literature
UnknownIdentification of six new susceptibility loci for invasive epithelial ovarian cancer.
Not available
S-EPMC4445140 | biostudies-literature
UnknownDifferentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
Not available
S-EPMC11408082 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
Sort   by:  
 Page size